MedTech Deals Worth $15.8 Billion in Q2
With 253 deals occurring during this year’s second quarter, the medical device industry experienced an 11% increase in deal activity versus its four-quarter average, according to a recent report released by analyst firm GlobalData. Venture financing accounted for nearly 75% of the deals (189 transactions), followed by mergers and acquisitions at 20% and private equity deals at 5% (13 deals). M&A led the pack when looking at deal value, which was estimated at about $13.6 billion. Venture capital financing was at $2 billion, followed by private equity at $211 million.
When looking at deal size, nearly 84% of the overall deal value was thanks to the top five transactions of the quarter, the largest of which was 3M’s acquisition of Acelity in May. The second-largest deal was Dassault Systemes’ acquisition of Medidata Solutions for $5.8 billion, followed by Boston Scientific taking VertiFlex for $465 million.
Related Articles
-
It is more important than ever for medical manufacturers to prepare for business interruption due to unexpected damage or natural disasters. From building a recovery team to securing proper insurance, there are many steps device manufacturers can take to recover…
-
Nondisclosure agreements (NDAs) can help protect trade secrets and build a framework for better cooperation and understanding between parties. Following are some key areas to consider when creating an NDA.
-
Veeva Vault CRM for Medtech is a unified customer relationship management (CRM) and content management application built for medtech sales teams, key account managers and medical affairs professionals.
-
Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks’ FFRangio System for the noninvasive diagnosis of CAD in the U.S., Europe and Japan, where it is commercially available.
